Isoray (NYSE:ISR) Now Covered by started coverage on shares of Isoray (NYSE:ISRGet Rating) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the stock.

Isoray Stock Performance

NYSE:ISR opened at $0.40 on Monday. The firm’s fifty day moving average is $0.33 and its 200-day moving average is $0.33. Isoray has a 52 week low of $0.19 and a 52 week high of $0.52. The firm has a market cap of $56.70 million, a P/E ratio of -6.65 and a beta of 1.18.

Isoray (NYSE:ISRGet Rating) last released its earnings results on Wednesday, September 28th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). Isoray had a negative net margin of 91.45% and a negative return on equity of 14.76%. The company had revenue of $2.51 million for the quarter, compared to the consensus estimate of $2.89 million. As a group, sell-side analysts anticipate that Isoray will post -0.05 earnings per share for the current year.

Isoray Company Profile

(Get Rating)

Isoray, Inc, together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.

Featured Stories

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with's FREE daily email newsletter.